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ABSTRACT
Repeated administration of amphetamine (AMPH) produces behavioral sensitization, 
a proposed model for the escalation of drug use characteristic of human addicts. β- 
Phenylethylamine (PEA) is an endogenous trace amine found in mammalian brain and 
resembles AMPH both structurally and behaviorally. Previously, it has been reported 
that chronic PEA administration produces behavioral sensitization to the challenges of 
AMPH. However, these data were obtained with very high amount of PEA for a 
relatively long period of time. Further, the effect of PEA challenge on the expression 
of behavioral sensitization developed by AMPH pre-exposures has not been tested yet. 
Thus, we examined in the present experiment the expression of behavioral sensitization 
with AMPH challenge after a mild chronic PEA treatment. Rats were repeatedly 
administered with systemic injections of saline, β-phenylethylamine (PEA) (10 or 50 
mg/kg), or amphetamine (AMPH) (1.5 mg/kg). When challenged a week after the last 
pre-injection, rats pre-exposed to either PEA or AMPH showed behavioral sensitization 
to AMPH (1.0 mg/kg), while these effects were not observed to PEA (50 mg/kg) itself. 
These results demonstrate that repeated exposure to PEA produces behavioral sensi-
tization to AMPH challenge, while PEA challenge has no effect on the expression of 
behavioral sensitization developed by AMPH pre-exposures, suggesting that PEA may 
play a role in the development of locomotor sensitization to AMPH, but not in the ex-
pression of it.
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INTRODUCTION
  β-Phenylethylamine (PEA) is an endogenous 
trace amine that is found in mammalian brain with 
highest levels in regions such as the caudate- 
putamen, olfactory tubercles, and nucleus accumbens 
(Berry, 2004). Both structurally and behaviorally, 
PEA resembles a psychostimulant drug amphetamine 
(AMPH) and has been implicated in human psy-
chiatric diseases like depression and schizophrenia, 
leading to propose it to be called as an ‘endo-
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genous AMPH’ (Burchett and Hicks, 2006).
  Repeated intermittent administration of AMPH 
produces behavioral sensitization, which is a pro-
posed model for the escalation of drug use and 
craving characteristic of human addicts (Robinson 
and Berridge, 1993). Evidence indicates that the 
development of sensitization by drugs like AMPH 
can be separated as two phases of induction and 
expression, in which different neuronal processes 
involved mediating distinct neuronal substrates in 
the brain (Cador et al., 1995; Vanderschuren and 
Kalivas, 2000). It has been reported that PEA 
increases locomotor activity in rodents similar to 
AMPH but with the less potency and duration of 
action (Dourish, 1981; Popplewell et al., 1986; Lapin, 
1996). Interestingly, it has been also shown that 
chronic systemic PEA administration produces 
behavioral sensitization to the challenges of AMPH 
as well as of PEA itself (Gianutsos and Chute, 
1986; Kuroki et al., 1990). However, these data were 
obtained after more than 21 days of daily PEA 
administrations, in which the amount of PEA used 
was very high compared to that of AMPH generally 
used in the procedure of developing AMPH sensi-
tization. Furthermore, the effect of PEA challenge 
on the expression of locomotor sensitization deve-
loped by AMPH pre-exposures has not been tested 
yet. Thus, we examined in the present experiment 
the expression of locomotor sensitization with AMPH 
challenge after a mild chronic PEA treatment, and 
vice versa, with a pre-exposure scheme of just 
several times of intermittent injections. 
MATERIALS AND METHODS
Subjects
  Male Sprague-Dawley rats weighing 230∼260 g 
on arrival were obtained from Samtako (Osan, 
Korea). They were housed three per cage in a 
12-hr light/dark cycle room with food and water 
available at all times. All procedures involving 
animals were conducted according to an approved 
IACUC protocol.
Drugs 
  PEA hydrochloride (Sigma Chemical, St. Louis, 
MO, USA) and d-AMPH sulfate (United States 
Pharmacopeial Convention, Inc., Rockville, MD, USA) 
were dissolved in sterile 0.9% saline. Their doses 
refer to the weight of the salt. 
Locomotor activity
  Locomotor activity was measured in a bank of 6 
activity boxes (35×25×40 cm) (IWOO Scientific Cor-
poration, Seoul, Korea) made of translucent Plexiglas 
and individually kept in larger PVC plastic sound 
attenuating cubicles. The floor of each box con-
sisted of 21 stainless steel rods (5 mm diameter) 
spaced 1.2 cm apart center-to-center. Two infrared 
light photocells (Med Associates, St. Albans, VT, 
USA) positioned 4.5 cm above the floor and spaced 
evenly along the longitudinal axis of the box 
estimated locomotor activity. 
Design and procedure
  Animals were treated for experimental procedures 
as follows. Experiment 1: Different four groups of 
rats were administered systemic injections of either 
saline, PEA (10 or 50 mg/kg), or AMPH (1.5 mg/kg) 
once a day with an interval of 2 or 3 days for a 
total of five times. Locomotor activities after injection 
were measured in activity boxes only on Day 1 and 
5, and they were home cage-injected for the rest of 
days during this drug pre-exposure phase. A week 
of drug-free withdrawal period after the last injec-
tion, they were all AMPH (1 mg/kg, i.p.) challenged, 
then immediately returned to the boxes and their 
locomotor activity measured for 1 hr. Experiment 2: 
Additional three groups of rats, administered syste-
mic injections of either saline, PEA (50 mg/kg), or 
AMPH (1.5 mg/kg), followed the same pre-exposure 
treatments as Experiment 1 above. A week after 
the last injection, they were all challenged by PEA 
(50 mg/kg, i.p.) and their locomotor activity mea-
sured for 1 hr. Throughout the procedures, when-
ever locomotor activity was measured, rats were 
always first habituated to the locomotor activity 
boxes for 1 hr before drug injections given. 
Statistical analyses 
  The data were analyzed with one-way or two-way 
between-within ANOVA (analysis of variance). Post- 
hoc Scheffé comparisons were made according to 
Kirk (1968). Differences between experimental con-
ditions were considered statistically significant when 
p＜0.05. 
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Fig. 1. Repeated exposure to PEA produces locomotor sensi-
tization to AMPH challenge. Data are illustrated as group mean 
(＋SEM) locomotor activity counts obtained for 1 hr following the 
drug injection during the pre-exposure period (A) and at the time 
of challenge (B). Time-course data at the challenge (C) are 
shown for only three groups of the four tested to clarify the 
effects of high dose of PEA. Numbers of rats in each group are 
9 to 10. Symbols indicate significant differences as revealed by 
post-hoc Scheffé comparisons following two-way between-within 
(for pre-exposure) and one-way (for challenge) ANOVA’s. ***p＜
0.001; AMPH compared with saline pre-exposed on day 1. **p＜
0.01, *p＜0.05; PEA (50 mg/kg) or AMPH compared with saline 
pre-exposed after AMPH challenge. †††p＜0.001; Day 5 com-
pared with day 1 in rats AMPH pre-exposed. 
RESULTS
  Fig. 1A shows the locomotor activity counts 
obtained in rats systemically injected with either 
saline, one of two doses of PEA (10 or 50 mg/kg) 
or AMPH during pre-exposure phase. The two-way 
between-within ANOVA conducted on these data 
revealed multiple significant effects of different 
pre-exposure groups [F(3,34)=83.91, p＜0.001], days 
[F(1,34)=9.98, p＜0.01] and a group×days interac-
tion [F(3,34)=8.12, p＜0.001]. As expected, AMPH 
compared to saline significantly increased locomotor 
activity response on day 1 and these effects were 
further enhanced when measured on day 5 (p＜ 
0.001). PEA, however, produced no effects on loco-
motor activity both acutely on day 1 and repeatedly 
on day 5. After a week of drug-free withdrawal 
period, AMPH compared to saline pre-exposed group 
of rats showed again a sensitized locomotor activity 
to AMPH challenge. Interestingly, PEA compared to 
saline pre-exposed group also showed a sensitized 
locomotor activity to this challenge (Fig. 1B). The 
ANOVA conducted on these data showed signi-
ficant effect of groups [F(3,34)=5.65, p＜0.004]. Post 
hoc Scheffé revealed that significant effects appe-
ared on high dose of PEA and AMPH (p＜0.05∼
0.01). Time-course data in Fig. 1C shows that the 
sensitized locomotor responses to AMPH challenge 
in PEA pre-exposed rats persisted apparently for up 
to the 30 min of testing similar to AMPH. 
  In a separate experiment, when challenged with 
PEA, however, rats pre-exposed a week earlier to 
either PEA (50 mg/kg) or AMPH showed locomotor 
activity that was not different from that displayed by 
saline pre-exposed rats (Fig. 2). The ANOVA conducted 
on these data showed no significant effects of 
groups [F(2,15)=0.09, p＜0.92]. 
DISCUSSION
  The present results demonstrate that repeated 
exposure to PEA produces locomotor sensitization 
to AMPH challenge, while PEA challenge has no 
effect on the expression of locomotor sensitization 
developed by AMPH pre-exposures. Previous studies 
have shown that chronic daily PEA injections deve-
lops behavioral sensitization which appeared after 
more than 21 days of treatments to the challenges 
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Fig. 2. PEA challenge a week after repeated exposure to either 
PEA or AMPH shows no difference in locomotor activity. Data 
are illustrated as group mean (＋SEM) locomotor activity counts 
obtained for 1 hr following the drug injection at the time of 
challenge (n=6/group). 
of AMPH as well as of PEA itself (Gianutsos and 
Chute, 1986; Kuroki et al., 1990). Our results are 
consistent with those in that chronic PEA produces 
behavioral sensitization to AMPH challenge. Further, 
it is evident in our results that only several times of 
intermittent PEA injections are sufficient enough to 
induce locomotor sensitization which is demonstrated 
by AMPH challenge after a week of withdrawal. 
However, contrary to the previous studies, PEA 
challenge did not evoke sensitized locomotion with 
our PEA pre-exposure procedures (Fig. 2), sug-
gesting that PEA-induced behavioral sensitization 
may require the heavier pre-exposure treatments 
(e.g., daily over 21 days) to express its develop-
ment to PEA itself. More interestingly, our results 
also showed that the same dose of PEA (50 mg/ 
kg) is not able to evoke the expression of loco-
motor sensitization induced by AMPH pre-exposures, 
although several injections of that dose are enough 
to induce behavioral sensitization as revealed by 
AMPH challenge a week after. These results suggest 
that PEA may have a more significant role in the 
induction than in the expression of behavioral 
sensitization by AMPH. As evidence indicates that 
the induction and expression of behavioral sensi-
tization are mediated by distinct neuronal substrates 
(e.g., the nucleus accumbens and ventral tegmental 
area) in the brain (Cador et al., 1995; Vanderschuren 
and Kalivas, 2000), it may be interesting in the 
future to further look at the effects of PEA in these 
sites on different phase of sensitization. 
  The precise mechanisms by which PEA influences 
the development of behavioral sensitization remain 
unknown. It may possibly exert its effects by influ-
encing dopaminergic neurotransmission in the brain 
similar to AMPH (Kalivas and Stewart, 1991). For 
example, it has been shown in rodents that PEA 
increases extracellular levels of dopamine in the 
nucleus accumbens and striatum (Nakamura et al., 
1998; Sotnikova et al., 2004), as well as in the 
ventral tegmental area (Ishida et al., 2005). 
However, others demonstrated that PEA-induced 
hyper-locomotor activity was inhibited by CPP, a 
competitive NMDA receptor antagonist (Lapin, 1996), 
suggesting that other neurotransmission than dopa-
mine may also be involved in mediating PEA effects 
on the locomotion as also shown for AMPH (Kalivas 
and Stewart, 1991; Kim et al., 2001). Due to recent 
identifications of receptors that are specifically acti-
vated by PEA (Borowsky et al., 2001), it may soon 
be revealed how PEA mediates information and 
thereby influences the development of behavioral 
sensitization. Because AMPH has been known to 
significantly increase PEA concentrations in brain 
regions importantly implicated in drug addiction 
such as frontal cortex, striatum, and the nucleus 
accumbens (Chuang et al., 1982; Karoum et al., 
1997), to know what PEA actually does in the brain 
will definitely contribute to better understanding for 
the mechanism of the development of behavioral 
sensitization by AMPH. 
  In summary, our present findings clearly show 
that only several times of repeated PEA injections 
are able to produce behavioral sensitization that is 
demonstrable by AMPH challenge, and further 
indicate, on the contrary, that PEA is not enough to 
evoke the expression of behavioral sensitization 
developed by AMPH as well as PEA with this 
scheme of pre-exposures. Thus, the present results 
may provide a new insight for the differential 
behavioral profile PEA may produce in relation with 
the development of behavioral sensitization by 
AMPH. 
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